R-nuucell selected by EP PerMed to validate a promising cancer therapy Portuguese biotechnology startup R-nuucell has been chosen to participate in the European Union’s EP PerMed program, a six-month initiative designed to advance precision medicine for cancer and other diseases. The Lisbon-based company was among eight startups selected for the program, which funds innovative projects…